Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9748975 | 1.00 | PDPK1 (0.54) | PDPK1CHRNA7HTR1AOPRM1OPRD1 | |
| SCHEMBL4863623 | 1.00 | PDPK1 (0.54) | PDPK1CHRNA7HTR1AOPRM1OPRD1 | |
| SCHEMBL9748978 | 1.00 | PDPK1 (0.54) | PDPK1CHRNA7HTR1AOPRM1OPRD1 | |
| SCHEMBL14367944 | 0.94 | PDPK1 (0.50) | PDPK1CHRNA7SIGMAR1 | |
| SCHEMBL9701818 | 0.94 | PDPK1 (0.50) | PDPK1CHRNA7SIGMAR1 | |
| SCHEMBL7620201 | 0.86 | PDPK1 (0.44) | PDPK1CHRNA7OPRM1OPRK1 | |
| SCHEMBL7620196 | 0.86 | PDPK1 (0.44) | PDPK1CHRNA7OPRM1OPRK1 | |
| SCHEMBL7620191 | 0.86 | PDPK1 (0.44) | PDPK1CHRNA7OPRM1OPRK1 | |
| SCHEMBL9813868 | 0.84 | SLC9A3 (0.47) | CHRNA7 | |
| SCHEMBL7617553 | 0.84 | CHRNA7 (0.45) | PDPK1CHRNA7OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014721-A1 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | FAGNOU KEITH (CA) | 2005-01-20 | — | — | US | claimed |
| EP-1498406-A1 | Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand | AstraZeneca AB (SE) | 2005-01-19 | — | — | EP | claimed |
| EP-1228024-B1 | NOVEL HYDRONAPHTHALENE COMPOUNDS, PREPARED BY A RHODIUM CATALYZED RING OPENING REACTION IN THE PRESENCE OF PHOSPHINE LIGAND | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | claimed |
| US-20030144275-A1 | Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |
| US-6525068-B1 | Such as 2-pyrrolidin-1-yl-1,2-dihydro-naphthalen-1-ol; reac-tion of oxabenzonorbornadienes with nucleophiles; pain, parkinson's disease, cancer, aids | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | claimed |
| US-20080300271-A1 | Novel compounds and a novel process for their preparation | FAGNOU KEITH | 2008-12-04 | — | — | US | disclosed |
| US-7420003-B2 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | disclosed |
| US-20050014721-A1 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | FAGNOU KEITH (CA) | 2005-01-20 | — | — | US | disclosed |
| EP-1498406-A1 | Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand | AstraZeneca AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1228024-B1 | NOVEL HYDRONAPHTHALENE COMPOUNDS, PREPARED BY A RHODIUM CATALYZED RING OPENING REACTION IN THE PRESENCE OF PHOSPHINE LIGAND | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-6784210-B2 | DECYCLIZATION OF OXABENZONORBORNADIENES OR AZABICYCLIC COMPOUNDS IN THE PRESENCE OF CATALYSTS TO FORM NAPHTHALENES, SUCH AS 2-METHOXY-1,2-DIHYDRONAPHTHALEN-1-OL, USED AS ANALGESICS, ANTICARCINOGENS OR VIRICIDES; CATALYSIS | ASTRAZENECA AB (SE) | 2004-08-31 | — | — | US | disclosed |
| US-20030144275-A1 | Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| US-6525068-B1 | Such as 2-pyrrolidin-1-yl-1,2-dihydro-naphthalen-1-ol; reac-tion of oxabenzonorbornadienes with nucleophiles; pain, parkinson's disease, cancer, aids | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300271-A1 | Novel compounds and a novel process for their preparation | NUDT1, NCL, NUCB2 | PDPK1 1513/4885CHRNA7 1464/4885HTR1A 2363/4885 |
| US-20050014721-A1 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | PARK7, OPRD1, OPRK1 | PDPK1 104/4885CHRNA7 2006/4885HTR1A 1018/4885 |
| US-20030144275-A1 | Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis | DDT, HPD, DHODH | PDPK1 1457/4885CHRNA7 2237/4885HTR1A 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.